Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 4/5 criteria met. Data as of 28/10/2026.
- ✅ Price trend passed
- ✅ Growth passed
- ✅ Debt passed
- ✅ P/E passed
- ❌ Correction failed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2018 → 2019: 107.82%
Price change 2019 → 2020: 0.63%
Price change 2020 → 2021: 78.36%
Price change 2021 → 2022: -46.29%
Price change 2022 → 2023: 57.68%
Price change 2023 → 2024: -11.96%
Price change 2024 → 2025: 12.95%
Price change 2025 → 2026: -2.52%
Price change 2026 (year to date): -1.41%
Financial growth
Revenue CAGR (8 years): 7.74%
Earnings CAGR (8 years): 33.37%
Growth status: positive trend (>1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 0.26
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 19.39
P/E < 25.0 (maximum threshold).
Correction (6 months)
Current correction: 6.19% from the high over 6 months.
Insufficient correction (< 10.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="VIRP.PA" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Virbac S.A. | 19.4 | 0.26 | +6.5 % | 🔒 |
| Emeis | – | 6.11 | +11.4 % | – |
| Clariane SE | 565.5 | 2.16 | +12.4 % | – |
| bioMérieux S.A. | 22.5 | 0.11 | +7.6 % | – |
| Lumibird S.A. | 37.3 | 0.71 | +9.8 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|